NCT01129011View on ClinicalTrials.gov

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions
Gastric Ulcer
Interventions
DRUG

PN400 (VIMOVO)

PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.

DRUG

Naproxen

Naproxen 500 mg dosed twice daily (bid) orally

Sponsors

Lead Sponsor

POZEN
All Listed Sponsors
lead

POZEN

INDUSTRY

NCT01129011 - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen | Biotech Hunter | Biotech Hunter